(Received for publication June 30, 1997) In the course of screening microorganisms isolated fromthe marineenvironment,fermentation samplesof culture LL-141352 were found to exhibit activity in the Biochemical Induction Assay (BIA), which detects agents that directly or indirectly initiate DNAdamage1}. This culture was originally isolated from an orange tunicate collected from the Pacific Ocean in proximity to Fiji and was subsequently identified as a new halophilic marine bacterium2). The BIA-active compounds isolated from fermentations of this culture were found to be the new phenazine antibiotics LL-14I352a and /?, which also exhibited activity in both our antibacterial and antitumor primary screens. Coincidently, a compoundidentical to LL-141352a, pelagiomicin-A, was also discovered from a marine bacterium isolated from a different marine environment by Imamura et al?\ We identified an additional component, LL-141352/?, which was found to be less active than the a component. Further details of in vitro and in vivo antibacterial, cytotoxic, and antitumor activities and the mechanism of antibacterial action are reported here.
The in vitro antibacterial activities against 15 Grampositive and 5 Gram-negative isolates were determined by the broth microdilution method4). LL-14I352a exhibited good Gram-positive activity (MIC, 0.25~2 jug/ml), but moderate to poor Gram-negative activity (MIC, 16~> 128 jug/ml). This data is consistent with the activities reported for pelagiomicin A3). LL-141352ŵ hich lacks the amino acid residue (see Fig. 1 LL-14I352a is identical to pelagiomicin A. was preferentially inhibited at all concentrations. The effect of drugs on the cellular uptake of radiolabeled precursors was determined by measuring radioactivity retained in saline-washed cells under the same experimental conditions. For each drug tested, uptake of the three radiolabeled precursors was unaffected relative to the specific inhibition of incorporation into TCAprecipitable material (Table 1) . BIA activity of LL141352a at a concentration as low as 0.08^g/spot further confirmed its DNA-damaging activity in bacteria. positive BIA response at a minimumconcentration of 0.003 jag per spot. Since LL-141352a and /? were found to be BIA active and to inhibit preferentially DNAsynthesis, they were tested for cytotoxicity against five humantumor cell lines with denned properties and against a normal bovine cell line (Table 2 ). Other phenazines isolated from diverse sources have been found to exhibit antitumor activity7'8*.
The mean IC50 values for LL-141352a and /? were 0.88 /ig/ml and 3.98 //g/ml, respectively, suggesting that the a componentis 4.5 times more cytotoxic than the jS. The presence of the amino acid residue in the a component may be facilitating its entry into the cells (Fig. 1) . The ratio of the IC50 value for A2780DDP, a cell line with enhanced DNArepair capability, to that of its parent A2780S9) for adriamycin, LL-14I352& and 8.5, and 3.3, respectively. These data suggest that the a component is less responsive to the enhanced DNArepair capability of A2780DDP. Antibiotic LL-141352a and /? were equipotent against a MIP multidrug-resistant colon carcinoma cell line and SW620, a comparable drug-sensitive line, suggesting that these compoundsare unaffected by the /?-glycoproteinmediated drug efflux pumplo~12). LL-14I352a appeared to be somewhat more active against the tumor cell lines than against the normal endothelial line. LL-141352a and LL-141352)5 were inactive in an in vivo P388 murine leukemia model at concentrations up to 8 mg/kg. Pelagiomicin A also was inactive against P388 in in vitro testing3*. Testing has not been conducted, however, in solid tumor models. Acute toxicity was observed at 16mg/kg. LL-14I352a and jS also failed to protect mice against a lethal S. aureus infection at doses up to 8mg/kg. The LD50 for LL-14I352a was estimated to be 16 mg/kg, but the /? component exhibited no toxicity at doses up to 32mg/kg. Lack of in vivo activity and a poor toxicological profile would most likely limit the 
